Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane/Tazobactam vs Meropenem in Pediatric cUTI
NCT03230838Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of ceftolozane + tazobactam in complicated urinary tract infection (cUTI), sponsored by Merck & Co.. Started Apr 2018; status: completed.
02
Drugs
ceftolozane + tazobactam
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT03230838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03230838.